Skip to main content

Table 2 Pre-period clinical characteristics (Commercial/Medicare, and Medicaid)

From: Characteristics of patients initiating raloxifene compared to those initiating bisphosphonates

  Commercial/Medicare Medicaid
  Raloxifene Bisphosphonates Raloxifene Bisphosphonates
  (N = 17,983) (N = 79,891) (N = 11,504) (N = 59,881)
Health status Mean (STD) Mean (STD) Mean (STD) Mean (STD)
CCI 0.5(1.1)* 0.7 (1.4) 0.9 (1.5)* 1.1 (1.6)
  % % % %
Any fracture 10.0* 14.6 9.4* 14.2
Hip 0.4* 1.3 0.6* 1.3
Vertebral 1.4* 2.6 1.5* 2.4
Non-vertebral 9.2* 13.3 8.5* 12.7
Screening     
BMD test 43.2* 63.8 20.9* 27.6
Mammogram 8.4* 10.6 8.7 9.2
Confounding conditions     
Breast cancer 3.5* 5.5 6.0* 6.9
Endocrine disease 13.9 13.8 20.3 20.8
HIV 0.0 0.0 0.1 0.1
Liver disease 1.9 1.9 3.6 3.2
Bone cancer 0.0†† 0.1 0.0 0.0
Other cancer 20.1 21.5 10.3 10.6
Alcoholism 0.1 0.1 0.1 0.1
Osteodystrophy 0.0 0.1 0.1 0.1
Nephritis 0.8* 1.1 1.9† 2.4
Rheumatoid arthritis 1.5* 2.7 2.4* 3.7
Any cardiovascular disease 5.9* 8.1 13.1 13.1
Thyroid disease 11.5* 12.6 8.3 7.9
Metabolic disorders 30.9† 29.7 25.5* 23.4
Osteoporosis 2.9* 6.9 5.3* 8.0
DVT/PE 0.0* 0.1 0.2† 0.4
Gastric ulcer 0.1 0.1 0.3 0.3
Peptic ulcer 0.1 0.0 0.6 0.5
Dysphagia 0.2 0.3 0.6 0.6
Gastroesophageal reflux 0.9 1.0 2.4 2.1
Gastritis 0.3 0.4 2.9* 2.2
Medications     
Glucocorticoids 13.4* 16.4 13.3* 16.6
Estrogen/HRT 38.4* 27.9 21.9* 13.7
Hormone deprivation therapy 1.2* 2.9 0.7* 1.6
Anticonvulsants 2.4* 3.1 5.4 5.8
Immunosuppressants 1.4* 2.6 1.1* 2.2
Resource utilization Mean (STD) Mean (STD) Mean (STD) Mean (STD)
Inpatient claims 0.1 (0.4)* 0.2 (0.5) 0.1 (0.5)* 0.1 (0.6)
ER claims 0.5 (2.0)* 0.6 (2.5) 2.1 (7.1)* 2.4 (8.4)
Outpatient claims 31.1 (32.7)* 36.4 (41.9) 49.0 (65.6)* 51.7 (70.3)
Rx claims 24.5 (24.9)* 26.2 (27.0) 46.9 (40.8) 49.9 (40.6)
  1. Comparisons of raloxifene to bisphosphonates are statistically significant at: *p < 0.0001; †p < 0.001; †† p < 0.01